阿斯利康宣布对华投资超1000亿元

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]